Jump to content

Veltuzumab

From Wikipedia, the free encyclopedia

Veltuzumab
Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	CD20
Clinical data
ATC code	none
Identifiers
CAS Number	728917-18-8^N
ChemSpider	none
UNII	BPD4DGQ314
Chemical and physical data
Formula	C₆₄₅₈H₉₉₁₈N₁₇₀₆O₂₀₂₆S₄₆
Molar mass	145349.06 g·mol⁻¹
^NY (what is this?) (verify)

Veltuzumab is a monoclonal antibody (targeted at CD20) which is being investigated for the treatment of non-Hodgkin's lymphoma.^[1]^[2] As of December 2011^[update], it is undergoing Phase I/II clinical trials.^[3] When used with milatuzumab it showed activity.^[4]

This drug was developed by Immunomedics, Inc. and was originally known as IMMU-106.^[5]

In August 2015 the US FDA granted it orphan drug status for immune thrombocytopenia (ITP).^[6] A phase II trial is planned to run for 5 years.^[6]

See also

CD20 antagonist

References

^ Statement On A Nonproprietary Name Adopted By The USAN Council - Veltuzumab, American Medical Association.
^ Rossi EA, Goldenberg DM, Cardillo TM, Stein R, Chang CH (October 2009). "CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas". Blood. 114 (18): 3864–71. doi:10.1182/blood-2009-06-228890. PMC 2773491. PMID 19710501.
^ Clinical trial number NCT00546793 for "Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL" at ClinicalTrials.gov
^ Christian BA, Poi M, Jones JA, Porcu P, Maddocks K, Flynn JM, et al. (June 2015). "The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma". British Journal of Haematology. 169 (5): 701–10. doi:10.1111/bjh.13354. PMC 7297055. PMID 25847298.
^ Zibelman M, Borghaei H, Olszanski AJ (2014). "Harnessing Innate Immunity". In Dubel S, Reichert JM (eds.). Handbook of Therapeutic Antibodies (2nd ed.). John Wiley & Sons. p. 791. doi:10.1002/9783527682423.ch27. ISBN 978-3-527-68244-7.
^ ^a ^b "FDA grants orphan drug designation to veltuzumab for ITP". HemOnc Today. Healio.com. August 4, 2015.

Monoclonal antibodies for tumors

Human	Adecatumumab^§ Amivantamab Ascrinvacumab^§ Atezolizumab (+hyaluronidase) Balstilimab^† Botensilimab Cixutumumab^§ Conatumumab^§ Daratumumab Drozitumab^§ Duligotumab^§ Dusigitumab^§ Enfortumab vedotin Enoticumab^§ Figitumumab^§ Flanvotumab^§ Ganitumab^† Glembatumumab vedotin^† Intetumumab^§ Ipilimumab Iratumumab^§ Istiratumab Icrucumab^§ Lexatumumab^§ Lucatumumab^§ Mapatumumab^§ Narnatumab^§ Necitumumab Nesvacumab^§ Nivolumab^# Ofatumumab Olaratumab^† Panitumumab Patritumab^§ Pembrolizumab^# Pritumumab^§ Radretumab^§ Ramucirumab Rilotumumab^† Robatumumab^§ Seribantumab^§ Sugemalimab Tarextumab^§ Tisotumab vedotin Teprotumumab^† Tovetumab^§ Vantictumab^§ Votumumab^§ Zalutumumab^†
Mouse	Abagovomab Altumomab pentetate Anatumomab mafenatox Arcitumomab Bectumomab Blinatumomab Capromab pendetide Detumomab Edrecolomab Ibritumomab tiuxetan Igovomab Lilotomab Minretumomab Mitumomab Nacolomab tafenatox Moxetumomab pasudotox Naptumomab estafenatox Oregovomab Pemtumomab^† Racotumomab Satumomab pendetide Solitomab Taplitumomab paptox Nofetumomab merpentan Pintumomab Tenatumomab Tositumomab
Chimeric	Amatuximab^§ Bavituximab^§ Brentuximab vedotin Carotuximab^† Cetuximab Derlotuximab biotin^§ Dinutuximab Ecromeximab^§ Ensituximab^§ Futuximab^§ Girentuximab^† Indatuximab ravtansine^§ Isatuximab Loncastuximab tesirine Margetuximab Mirvetuximab soravtansine Rituximab^# Siltuximab Ublituximab Zolbetuximab
Humanized	Abituzumab^§ Alemtuzumab Axatilimab Belantamab mafodotin Bevacizumab Bivatuzumab mertansine^§ Brontictuzumab^§ Cantuzumab mertansine^§ Cantuzumab ravtansine^§ Cirmtuzumab Citatuzumab bogatox^§ Clivatuzumab tetraxetan Cofetuzumab pelidotin Dacetuzumab^§ Demcizumab^§ Dalotuzumab^§ Denintuzumab mafodotin^§ Elotuzumab Emactuzumab Emibetuzumab^§ Enoblituzumab^§ Epcoritamab Etaracizumab^§ Farletuzumab^§ Ficlatuzumab^§ Flotetuzumab^§ Gemtuzumab ozogamicin Glofitamab Imgatuzumab^§ Inotuzumab ozogamicin Labetuzumab^§ Lifastuzumab vedotin^§ Lintuzumab^§ Lorvotuzumab mertansine^§ Lumretuzumab^§ Matuzumab^§ Milatuzumab^§ Naxitamab Nimotuzumab^† Obinutuzumab Ocaratuzumab^§ Odronextamab Otlertuzumab^§ Onartuzumab^§ Oportuzumab monatox^† Parsatuzumab^§ Pertuzumab Pinatuzumab vedotin^§ Polatuzumab vedotin Rosmantuzumab Rovalpituzumab tesirine^† Sacituzumab govitecan Sibrotuzumab^§ Simtuzumab^§ Sofituzumab vedotin^§ Tacatuzumab tetraxetan^§ Tigatuzumab^§ Trastuzumab^# (+deruxtecan / +emtansine) Tucotuzumab celmoleukin^§ Vandortuzumab vedotin^§ Vanucizumab^§ Veltuzumab^§ Vorsetuzumab mafodotin^§
Rat/mouse hybrid	Catumaxomab Ertumaxomab^§
Chimeric + humanized	Depatuxizumab mafodotin^† Duvortuxizumab Ontuxizumab^§

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Veltuzumab&oldid=1177181460"